Abstract:Percutaneous coronary intervention (PCI) is currently the main method for treating coronary artery stenosis, but the incidence of restenosis after PCI is relatively high. Restenosis, the narrowing of blood vessels by more than 50% of the normal diameter after PCI, severely compromises the therapeutic efficacy. Therefore, preventing postinterventional restenosis is important. Vascular restenosis is mainly associated with endothelial injury, the inflammatory response, the proliferation and migration of vascular smooth muscle cells (VSMCs), excessive deposition of extracellular matrix (ECM) and intimal hyperplasia (IH) and is usually prevented by administering antiproliferative or anti-inflammatory drugs through drug-eluting stents (DESs); however, DESs can lead to uncontrolled drug release. In addition, as extracorporeal implants, they can cause inflammation and thrombosis, resulting in suboptimal treatment. Therefore, there is an urgent need for a drug carrier with controlled drug release and high biocompatibility for in vivo drug delivery to prevent restenosis. The development of nanotechnology has enabled the preparation of nanoparticle drug carriers with low toxicity, high drug loading, high biocompatibility, precise targeting, controlled drug release and excellent intracellular delivery ability. This review summarizes the advantages of nanoparticle drug carriers for treating vascular restenosis, as well as how nanoparticles have improved targeting, slowed the release of therapeutic agents, and prolonged circulation in vivo to prevent vascular restenosis more effectively. The overall purpose of this review is to present an overview of nanoparticle therapy for vascular restenosis. We expect these findings to provide insight into nanoparticle-based therapeutic approaches for vascular restenosis.

Review: Research Progress and Future Prospects for Promoting Endothelialization on Endovascular Stents and Preventing Restenosis

Endothelial Progenitor Cells and In-stent Restenosis.

The Research Progress in Intravascular Stent Endothelialization

The Research Progress of Endothelial Progenitor Cell Therapy in Re-endothelialization after Percutaneous Coronary Stent Implantation

Recent Strategies for Improving Hemocompatibility and Endothelialization of Cardiovascular Devices and Inhibition of Intimal Hyperplasia

Progress and Prospects of Endothelial Progenitor Cell Therapy in Coronary Stent Implantation

The Intravascular Stent and Endothelialization Research

Endothelial Injury and Its Repair Strategies after Intravascular Stents Implantation

Recent Advances in Cardiovascular Stent for Treatment of In-Stent Restenosis: Mechanisms and Strategies

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Surface engineering of cardiovascular stent with endothelial cell selectivity for in vivo re-endothelialisation.

Survey of coronary stents development for restenosis prevention]

Endothelialization strategy of implant materials surface: The newest research in recent 5 years

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Endothelial Repair by Stem and Progenitor Cells

Nanoparticle-based Approaches for Treating Restenosis after Vascular Injury

Surface Modification and Endothelialization of Biomaterials As Potential Scaffolds for Vascular Tissue Engineering Applications

Vegf-Transfected Human Endothelial Cell Coating On Stents Promotes Re-Endothelization And Inhibits In-Stent Restenosis

Fully Biodegradable Stents and Strategy of Reendothelialization

The Research in Hemodynamic Characteristics of Vessels after Stent Implantion

Advances in the development of biodegradable coronary stents: A translational perspective